CG Oncology (NASDAQ:CGON) Trading Down 7.5% – What’s Next?

CG Oncology, Inc. (NASDAQ:CGON)’s share price was down 7.5% during mid-day trading on Thursday . The company traded as low as $69.00 and last traded at $68.4450. Approximately 431,027 shares traded hands during mid-day trading, a decline of 65% from the average daily volume of 1,220,286 shares. The stock had previously closed at $74.00.

CG Oncology News Summary

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating on CG Oncology and maintained a $100 price target, suggesting analysts still see meaningful upside from current levels.
• Positive Sentiment: The brokerage also lifted its FY2030 earnings estimate, indicating confidence in the company’s longer-term commercial potential.
• Neutral Sentiment: CG Oncology presented at the Bank of America Global Healthcare Conference, which kept investor attention on the story but did not include any clearly market-moving new data. Article Title
• Negative Sentiment: HC Wainwright cut its earnings estimates for Q2 2026, Q3 2026, Q4 2026, FY2026, FY2027, and FY2028, reinforcing the view that losses may persist longer than previously expected.
• Negative Sentiment: The updated forecasts point to larger near-term EPS losses, which can weigh on biotech stocks when investors focus on the path to profitability.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on CGON shares. Piper Sandler increased their price objective on CG Oncology from $55.00 to $70.00 and gave the stock an “overweight” rating in a report on Friday, January 16th. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a report on Monday, April 20th. Wall Street Zen cut shares of CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. JPMorgan Chase & Co. boosted their price target on shares of CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research report on Monday. Finally, Royal Bank Of Canada upped their price target on CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a research note on Monday. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, CG Oncology has an average rating of “Moderate Buy” and an average price target of $81.73.

CG Oncology Stock Down 6.2%

The firm has a fifty day moving average price of $66.77 and a two-hundred day moving average price of $53.68. The stock has a market capitalization of $6.12 billion, a P/E ratio of -29.53 and a beta of 0.41.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The company had revenue of $1.08 million during the quarter, compared to analyst estimates of $0.45 million. Sell-side analysts anticipate that CG Oncology, Inc. will post -2.77 earnings per share for the current fiscal year.

Insider Transactions at CG Oncology

In other news, Director James Mulay sold 15,600 shares of CG Oncology stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $73.01, for a total value of $1,138,956.00. Following the completion of the sale, the director directly owned 15,600 shares in the company, valued at $1,138,956. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On CG Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Sei Investments Co. raised its position in CG Oncology by 111.6% in the first quarter. Sei Investments Co. now owns 18,089 shares of the company’s stock worth $1,225,000 after acquiring an additional 9,542 shares during the period. First Trust Advisors LP grew its stake in shares of CG Oncology by 83.3% during the 1st quarter. First Trust Advisors LP now owns 333,192 shares of the company’s stock valued at $22,550,000 after acquiring an additional 151,394 shares during the period. KBC Group NV purchased a new stake in CG Oncology in the 1st quarter worth approximately $78,000. Jennison Associates LLC raised its stake in CG Oncology by 68.5% during the 1st quarter. Jennison Associates LLC now owns 476,136 shares of the company’s stock worth $32,225,000 after acquiring an additional 193,630 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in CG Oncology by 7.7% during the first quarter. Bank of New York Mellon Corp now owns 167,030 shares of the company’s stock valued at $11,305,000 after purchasing an additional 11,874 shares in the last quarter. Hedge funds and other institutional investors own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.